The WHO estimates up to 700,000 patients died in of multidrug resistant bacterial infections globally in 2016. This rise of multidrug resistant bacteria, prompted researchers to explore phage therapy again with spectacular successes. Several publications have recently reported spectacular successes in the fight against MDR bacterial infections in humans but also life stock. While in the past phage therapy was shunned by pharma companies for various challenges (see The dawn of phage therapy. Sana Rehman et al. https://doi.org/10.1002/rmv.2041), now the commercial potential and advances in genetics have enticed also biotech companies to exploit the potential of phage therapy as a secret weapon to kill superbugs. Also at the Vienna Biocenter our neighbour Phagomed explores an individual approach to commercialise phagetherapy.